Understanding Breast Cancer Survivors’ Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence
- 230 Downloads
Adjuvant hormonal therapy is recommended for women with hormone receptor (HR)-positive breast cancer. Though critical, many patients are non-adherent to this therapy. Few scales have been developed to specifically address beliefs about adjuvant hormonal therapy. This study explores the clarity and relevance of the Beliefs about Medicine Questionnaire (BMQ) in the context of adherence behaviors to hormonal therapy in Black and White breast cancer survivors. We recruited women diagnosed with HR-positive cancer from the Washington, DC, area. An interviewer administered a standardized survey and conducted a cognitive interview. Participants rated the BMQ across three areas: relevance, difficulty, and clarity. We coded whether the comments identified item level issues: limited applicability, unclear reference, unclear perspective, or wording or tone. In-depth interviews were conducted with women who prematurely discontinued hormone therapy. The sample (n = 30) was equally split between Black and White survivors. On average, women were 57.9 years old (SD = 9.0). Overall 77% rated scale as relevant. Cognitive interviews revealed areas of perceived limited acceptability such as the notion of becoming too dependent or the notion of becoming worse if not taking the medication. Women who discontinued hormonal therapy (n = 2) felt ambivalent towards hormonal therapy as they reported having both positive and negative beliefs about the medication. Our study findings suggest new areas for further research and instrument development to accurately measure self-reported beliefs about hormonal therapy by HR-positive breast cancer survivors.
KeywordsBreast cancer Cognitive interviews Survivors Medication beliefs
This work was funded by the National Cancer Institute (Sheppard: PI, grant number: R01CA154848; Hurtado de Mendoza and Sheppard: MPI, grant number: R03CA191543-01A1) and the National Center for Research Resources (NCRR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), through the Clinical and Translational Science Awards Program (CTSA) (Jensen: KL2 TR000102).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they do not have conflict of interest.
- 1.Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrutia G, Valentini M, Wang Y, Peto R, Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. doi: 10.1016/S0140-6736(12)61963-1 Google Scholar
- 2.Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. doi: 10.1007/s10549-010-1132-4 Google Scholar
- 3.Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J, Guth AA (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. doi: 10.1200/JCO.2005.04.5799 Google Scholar
- 4.Horne, R. and J. Weinman (1999) Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom ResGoogle Scholar
- 5.Silliman, R. A., E. Guadagnoli, W. Rakowski, M. B. Landrum, T. L. Lash, R. Wolf, A. Fink, P. A. Ganz, J. Gurwitz, C. Borbas and V. Mor (2002) Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical OncologyGoogle Scholar
- 6.Lash, T. L., M. P. Fox, J. L. Westrup, A. K. Fink and R. A. Silliman (2006) Adherence to tamoxifen over the five-year course. Breast cancer research and treatmentGoogle Scholar
- 7.Fink, A. K., J. Gurwitz, W. Rakowski, E. Guadagnoli and R. A. Silliman (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical OncologyGoogle Scholar
- 8.Bickell, N. A., J. Weidmann, K. Fei, J. J. Lin and H. Leventhal. (2009) Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust. Journal of Clinical Oncology: official journal of the American Society of Clinical OncologyGoogle Scholar
- 10.Collins, D. (2003) Pretesting survey instruments: an overview of cognitive methods. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitationGoogle Scholar
- 11.Daugherty, Sarah, Lauren Harris-Kojetin, Claudia Squire, Elizabeth Jaël and L. Harris-Kojetin (2001) Maximizing the quality of cognitive interviewing data: An exploration of three approaches and their informational contributionsGoogle Scholar
- 12.Jobe, Jared B. (2003) Cognitive psychology and self-reports: models and methods. Quality of Life ResearchGoogle Scholar
- 14.Pellegrini, I., A. Sarradon-Eck, P. B. Soussan, A. C. Lacour, R. Largillier, A. Tallet, C. Tarpin and C. Julian-Reynier (2010) Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients' point of view. Psycho-oncologyGoogle Scholar
- 15.Conner, M., R. Povey, P. Sparks, R. James and R. Shepherd. (2003) Moderating role of attitudinal ambivalence within the theory of planned behaviour. The British journal of social psychology / the British Psychological Society. doi: 10.1348/014466603763276135